Suppr超能文献

代谢组重排促进乳腺癌内分泌治疗耐药。

Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.

机构信息

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.

Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

出版信息

Cancer Res. 2024 Jan 16;84(2):291-304. doi: 10.1158/0008-5472.CAN-23-0184.

Abstract

UNLABELLED

Approximately one-third of endocrine-treated women with estrogen receptor alpha-positive (ER+) breast cancers are at risk of recurrence due to intrinsic or acquired resistance. Thus, it is vital to understand the mechanisms underlying endocrine therapy resistance in ER+ breast cancer to improve patient treatment. Mitochondrial fatty acid β-oxidation (FAO) has been shown to be a major metabolic pathway in triple-negative breast cancer (TNBC) that can activate Src signaling. Here, we found metabolic reprogramming that increases FAO in ER+ breast cancer as a mechanism of resistance to endocrine therapy. A metabolically relevant, integrated gene signature was derived from transcriptomic, metabolomic, and lipidomic analyses in TNBC cells following inhibition of the FAO rate-limiting enzyme carnitine palmitoyl transferase 1 (CPT1), and this TNBC-derived signature was significantly associated with endocrine resistance in patients with ER+ breast cancer. Molecular, genetic, and metabolomic experiments identified activation of AMPK-FAO-oxidative phosphorylation (OXPHOS) signaling in endocrine-resistant ER+ breast cancer. CPT1 knockdown or treatment with FAO inhibitors in vitro and in vivo significantly enhanced the response of ER+ breast cancer cells to endocrine therapy. Consistent with the previous findings in TNBC, endocrine therapy-induced FAO activated the Src pathway in ER+ breast cancer. Src inhibitors suppressed the growth of endocrine-resistant tumors, and the efficacy could be further enhanced by metabolic priming with CPT1 inhibition. Collectively, this study developed and applied a TNBC-derived signature to reveal that metabolic reprogramming to FAO activates the Src pathway to drive endocrine resistance in ER+ breast cancer.

SIGNIFICANCE

Increased fatty acid oxidation induced by endocrine therapy activates Src signaling to promote endocrine resistance in breast cancer, which can be overcome using clinically approved therapies targeting FAO and Src.

摘要

未加标签

约三分之一的雌激素受体阳性(ER+)乳腺癌内分泌治疗女性由于内在或获得性耐药而有复发风险。因此,了解 ER+乳腺癌内分泌治疗耐药的机制对于改善患者治疗至关重要。已经表明,线粒体脂肪酸β氧化(FAO)是三阴性乳腺癌(TNBC)中的主要代谢途径,可激活Src 信号。在这里,我们发现 ER+乳腺癌中增加 FAO 的代谢重编程是对内分泌治疗产生耐药性的一种机制。在 TNBC 细胞中抑制 FAO 限速酶肉碱棕榈酰转移酶 1(CPT1)后,从转录组学、代谢组学和脂质组学分析中得出了一个与代谢相关的综合基因特征,该 TNBC 衍生特征与 ER+乳腺癌患者的内分泌耐药显著相关。分子、遗传和代谢组学实验鉴定出在内分泌耐药的 ER+乳腺癌中 AMPK-FAO-氧化磷酸化(OXPHOS)信号的激活。体外和体内的 CPT1 敲低或 FAO 抑制剂治疗显著增强了 ER+乳腺癌细胞对内分泌治疗的反应。与之前在 TNBC 中的发现一致,内分泌治疗诱导的 FAO 激活了 ER+乳腺癌中的 Src 通路。Src 抑制剂抑制了内分泌耐药肿瘤的生长,并且通过 CPT1 抑制进行代谢启动可以进一步增强疗效。总之,这项研究开发并应用了一个源自 TNBC 的特征来揭示,代谢重编程为 FAO 激活 Src 通路,从而推动 ER+乳腺癌的内分泌耐药。

意义

内分泌治疗诱导的脂肪酸氧化增加激活 Src 信号,促进乳腺癌的内分泌耐药,使用针对 FAO 和 Src 的临床批准疗法可以克服这种耐药性。

相似文献

1
Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.
Cancer Res. 2024 Jan 16;84(2):291-304. doi: 10.1158/0008-5472.CAN-23-0184.
2
Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer.
Cell Rep. 2016 Mar 8;14(9):2154-2165. doi: 10.1016/j.celrep.2016.02.004. Epub 2016 Feb 25.
4
Low GPR81 in ER breast cancer cells drives tamoxifen resistance through inducing PPARα-mediated fatty acid oxidation.
Life Sci. 2024 Aug 1;350:122763. doi: 10.1016/j.lfs.2024.122763. Epub 2024 May 31.
6
Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers.
BMC Cancer. 2018 Aug 9;18(1):805. doi: 10.1186/s12885-018-4626-9.
8
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Nat Med. 2016 Apr;22(4):427-32. doi: 10.1038/nm.4055. Epub 2016 Mar 7.
10
Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
Biochem Biophys Res Commun. 2020 Dec 17;533(4):672-678. doi: 10.1016/j.bbrc.2020.09.143. Epub 2020 Oct 6.

引用本文的文献

1
Cancer stem cells in personalized therapy: mechanisms, microenvironment crosstalk, and therapeutic vulnerabilities.
Front Cell Dev Biol. 2025 Jul 30;13:1619597. doi: 10.3389/fcell.2025.1619597. eCollection 2025.
2
Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression.
PLoS One. 2025 Jul 28;20(7):e0328698. doi: 10.1371/journal.pone.0328698. eCollection 2025.
5
The role and mechanism of fatty acid oxidation in cancer drug resistance.
Cell Death Discov. 2025 Jun 13;11(1):277. doi: 10.1038/s41420-025-02554-1.
6
LIMK1 as a Novel Kinase of β-Catenin Promotes Esophageal Cancer Metastasis by Cooperating With CDK5.
Adv Sci (Weinh). 2025 Aug;12(29):e03223. doi: 10.1002/advs.202503223. Epub 2025 Jun 6.
7
8
Tumor-derived extracellular vesicles: key drivers of immunomodulation in breast cancer.
Front Immunol. 2025 Mar 4;16:1548535. doi: 10.3389/fimmu.2025.1548535. eCollection 2025.
9
Mesenchymal Stem Cell-Derived Exosomes in Cancer Resistance Against Therapeutics.
Cancers (Basel). 2025 Feb 27;17(5):831. doi: 10.3390/cancers17050831.

本文引用的文献

1
SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.
Breast Cancer Res. 2022 Dec 29;24(1):99. doi: 10.1186/s13058-022-01596-y.
2
Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1.
Breast Cancer. 2022 Jul;29(4):748-760. doi: 10.1007/s12282-022-01356-y. Epub 2022 May 5.
3
Molecular analysis of TCGA breast cancer histologic types.
Cell Genom. 2021 Dec 8;1(3). doi: 10.1016/j.xgen.2021.100067.
4
Estrogens and the regulation of glucose metabolism.
World J Diabetes. 2021 Oct 15;12(10):1622-1654. doi: 10.4239/wjd.v12.i10.1622.
6
Nuclear Receptor-Mediated Metabolic Reprogramming and the Impact on HR+ Breast Cancer.
Cancers (Basel). 2021 Sep 26;13(19):4808. doi: 10.3390/cancers13194808.
8
Metabolic reprograming confers tamoxifen resistance in breast cancer.
Chem Biol Interact. 2021 Sep 25;347:109602. doi: 10.1016/j.cbi.2021.109602. Epub 2021 Jul 28.
9
Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer.
Cancers (Basel). 2021 Mar 6;13(5):1132. doi: 10.3390/cancers13051132.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验